| Outcomes | Illustrative comparative risks (95% CI) | Relative effect (95 % CI) | No of participants (studies) | Quality of the evidence (GRADE) | |
|---|---|---|---|---|---|
| Assumed risk | Corresponding risk | ||||
| GnRH agonist (LA depot IM) + placebo IN | GnRH agonist (nafarelin IN) + placebo IM | ||||
| Relief of painful symptoms – Pelvic tenderness Follow-up: 6 months1 | 624 per 1,000 | 536 per 1,000 (418 to 680) | RR 0.86 (0.67 to 1.09) | 192 (1 study) | ⊕⊕⊝⊝ Low2 |
| Relief of painful symptoms–Pelvic induration Follow-up: 6 months1 | 813 per 1,000 | 740 per 1,000 (634 to 862) | RR 0.91 (0.78 to 1.06) | 190 (1 study) | ⊕⊕⊝⊝ Low2 |
CI: confidence interval; GnRH: gonadotrophin releasing hormone; IM: intramuscular; IN: intranasal; RR: risk ratio
Assessed after the end of the treatment period
Quality of evidence was downgraded by 2 points owing to very serious imprecision: CI crosses 2 default thresholds
From: 11, Management strategies
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.